304 related articles for article (PubMed ID: 16870417)
1. Human Vgamma9Vdelta2 T cells: promising new leads for immunotherapy of infections and tumors.
Bonneville M; Scotet E
Curr Opin Immunol; 2006 Oct; 18(5):539-46. PubMed ID: 16870417
[TBL] [Abstract][Full Text] [Related]
2. Early triggering of exclusive IFN-gamma responses of human Vgamma9Vdelta2 T cells by TLR-activated myeloid and plasmacytoid dendritic cells.
Devilder MC; Allain S; Dousset C; Bonneville M; Scotet E
J Immunol; 2009 Sep; 183(6):3625-33. PubMed ID: 19710464
[TBL] [Abstract][Full Text] [Related]
3. IL-21-mediated potentiation of antitumor cytolytic and proinflammatory responses of human V gamma 9V delta 2 T cells for adoptive immunotherapy.
Thedrez A; Harly C; Morice A; Salot S; Bonneville M; Scotet E
J Immunol; 2009 Mar; 182(6):3423-31. PubMed ID: 19265120
[TBL] [Abstract][Full Text] [Related]
4. [Tgammadelta lymphocytes in oncology: unconventional killer lymphocytes].
Catros V; Toutirais O; Bouet F; Cabillic F; Desille M; Fournié JJ
Med Sci (Paris); 2010 Feb; 26(2):185-91. PubMed ID: 20188051
[TBL] [Abstract][Full Text] [Related]
5. Innate immune functions of human gammadelta T cells.
Beetz S; Wesch D; Marischen L; Welte S; Oberg HH; Kabelitz D
Immunobiology; 2008; 213(3-4):173-82. PubMed ID: 18406365
[TBL] [Abstract][Full Text] [Related]
6. Repeated systemic administrations of both aminobisphosphonates and human Vγ9Vδ2 T cells efficiently control tumor development in vivo.
Santolaria T; Robard M; Léger A; Catros V; Bonneville M; Scotet E
J Immunol; 2013 Aug; 191(4):1993-2000. PubMed ID: 23836057
[TBL] [Abstract][Full Text] [Related]
7. Metabolite antigens and pathway incompatibility.
Honda W; Kawashima S; Kanehisa M
Genome Inform; 2006; 17(1):184-94. PubMed ID: 17503368
[TBL] [Abstract][Full Text] [Related]
8. Immune response of human propagated gammadelta-T-cells to neuroblastoma recommend the Vdelta1+ subset for gammadelta-T-cell-based immunotherapy.
Schilbach K; Frommer K; Meier S; Handgretinger R; Eyrich M
J Immunother; 2008; 31(9):896-905. PubMed ID: 18832998
[TBL] [Abstract][Full Text] [Related]
9. Vgamma9Vdelta2 T cells use a combination of mechanisms to limit the spread of the pathogenic bacteria Brucella.
Oliaro J; Dudal S; Liautard J; Andrault JB; Liautard JP; Lafont V
J Leukoc Biol; 2005 May; 77(5):652-60. PubMed ID: 15668339
[TBL] [Abstract][Full Text] [Related]
10. Self/non-self discrimination by human gammadelta T cells: simple solutions for a complex issue?
Thedrez A; Sabourin C; Gertner J; Devilder MC; Allain-Maillet S; Fournié JJ; Scotet E; Bonneville M
Immunol Rev; 2007 Feb; 215():123-35. PubMed ID: 17291284
[TBL] [Abstract][Full Text] [Related]
11. Human Vgamma9Vdelta2 T cells: from signals to functions.
Nedellec S; Bonneville M; Scotet E
Semin Immunol; 2010 Aug; 22(4):199-206. PubMed ID: 20447835
[TBL] [Abstract][Full Text] [Related]
12. The multifunctionality of human Vγ9Vδ2 γδ T cells: clonal plasticity or distinct subsets?
Kabelitz D; He W
Scand J Immunol; 2012 Sep; 76(3):213-22. PubMed ID: 22670577
[TBL] [Abstract][Full Text] [Related]
13. γδ T cells develop, respond and survive - with a little help from CD27.
Born WK; O'Brien RL
Eur J Immunol; 2011 Jan; 41(1):26-8. PubMed ID: 21182073
[TBL] [Abstract][Full Text] [Related]
14. Chemokine receptors expression and migration potential of tumor-infiltrating and peripheral-expanded Vgamma9Vdelta2 T cells from renal cell carcinoma patients.
Viey E; Lucas C; Romagne F; Escudier B; Chouaib S; Caignard A
J Immunother; 2008 Apr; 31(3):313-23. PubMed ID: 18317356
[TBL] [Abstract][Full Text] [Related]
15. Gammadelta T cell modulation in anticancer treatment.
Caccamo N; Dieli F; Meraviglia S; Guggino G; Salerno A
Curr Cancer Drug Targets; 2010 Feb; 10(1):27-36. PubMed ID: 20088797
[TBL] [Abstract][Full Text] [Related]
16. Lysis of a broad range of epithelial tumour cells by human gamma delta T cells: involvement of NKG2D ligands and T-cell receptor- versus NKG2D-dependent recognition.
Wrobel P; Shojaei H; Schittek B; Gieseler F; Wollenberg B; Kalthoff H; Kabelitz D; Wesch D
Scand J Immunol; 2007; 66(2-3):320-8. PubMed ID: 17635809
[TBL] [Abstract][Full Text] [Related]
17. A regulatory cross-talk between Vgamma9Vdelta2 T lymphocytes and mesenchymal stem cells.
Martinet L; Fleury-Cappellesso S; Gadelorge M; Dietrich G; Bourin P; Fournié JJ; Poupot R
Eur J Immunol; 2009 Mar; 39(3):752-62. PubMed ID: 19197941
[TBL] [Abstract][Full Text] [Related]
18. Perspectives of gammadelta T cells in tumor immunology.
Kabelitz D; Wesch D; He W
Cancer Res; 2007 Jan; 67(1):5-8. PubMed ID: 17210676
[TBL] [Abstract][Full Text] [Related]
19. Efficient killing of human colon cancer stem cells by gammadelta T lymphocytes.
Todaro M; D'Asaro M; Caccamo N; Iovino F; Francipane MG; Meraviglia S; Orlando V; La Mendola C; Gulotta G; Salerno A; Dieli F; Stassi G
J Immunol; 2009 Jun; 182(11):7287-96. PubMed ID: 19454726
[TBL] [Abstract][Full Text] [Related]
20. F1-adenosine triphosphatase displays properties characteristic of an antigen presentation molecule for Vgamma9Vdelta2 T cells.
Mookerjee-Basu J; Vantourout P; Martinez LO; Perret B; Collet X; Périgaud C; Peyrottes S; Champagne E
J Immunol; 2010 Jun; 184(12):6920-8. PubMed ID: 20483757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
